Kris Vaddi has been appointed as the Chief Executive Officer of Prelude Therapeutics Incorporated.
1 report, 1 independent
Updated Aug 14
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Kris Vaddi has been appointed as the Chief Executive Officer of Prelude Therapeutics Incorporated.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Kris Vaddi
researcher
Nothing else this week.
-
Prelude Therapeutics Incorporated (United States)
company in Wilmington, United States
Nothing else this week.
Coverage
Newest first; wire copies grouped- GlobeNewswirePrelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update PRT7732, once daily oral SMARCA2 degrader, currently enrolling at the seventh dosing cohort (125 mg);